Hospitals & Providers

Latest News


CME Content


Entresto is the first in a new class of drugs, valsartan combined with sacubitril, a pro-drug of a compound that is a receptor‐neprilysin inhibitor (ARNI). It is taken orally twice daily. It was approved for heart failure patients with reduced ejection fraction based on the PARADIGM-HF trial.

Reducing hospital-acquired infections has become a top priority for hospitals in the face of new penalties from CMS.